Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Experts Discuss Pros and Cons of Treatment Approaches in PV

BMFcases

T. Bat, A. Tefferi

2024 Updates in PV/ET

University of Colorado Division of Hematology

B. McMahon

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

BMFcases

T. Bat, A. Tefferi

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…

BMFcases

T. Bat, A. Tefferi

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

R. Mesa

When to Switch From Hydroxyurea to Ruxolitinib in PV

Prithviraj Bose

Counseling Patients With Newly Diagnosed PV or ET

Krisstina Gowin

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Top 5 Impactful MPN Abstracts From Summer Conferences

Insights from 2024 EHA Annual Meeting

P. Bose

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

State of the Art and Next Questions: MPN

SOHO Highlights: State of the Art and Next Questions

J. Mascarenhas